Immunotherapy is now considered a cornerstone of treatment for many forms of cancer, and its adoption has risen rapidly. As these treatments offer hope for patients in the form of longer and better-quality lives, as well as significant revenues for pharmaceuticals in the range of tens of billions of dollars, questions are arising about their broad use across types and stages of cancer.
Raphael Cohen
VP AI and Engineering
With expertise in machine learning, cloud computing, and healthcare, Raphael translates complex technical challenges into practical healthcare solutions. He’s pioneered ML platforms to drive innovations in radiology, pathology, and anesthesia while simultaneously improving operational efficiency and scale. Outside of work, he’s an avid cyclist who regularly participates in the Pan-Mass Challenge, enjoys hiking the White Mountains, and is often found playing guitar. He received a BS in Computer Science and Applied Mathematics from Brandeis University.